MSCI 689: Career Development for the Biomedical PhD Scientist Introduction to Medical Writing and Drug Development

Similar documents
Japanese submission/approval from programming perspective

STRATEGIC RESOURCING. inventivhealthclinical.com

Senior Regulatory Affairs Executive AREAS OF EXPERTISE

Drug Registration in BRICS countries: Opportunities and Challenges. Judith ter Horst 1 November 2018

MEDICAL WRITING. Zhiyun Lynn Guan Medical Writer, Medtronic April 9, 2018

PharmaSUG 2012 Paper #IB01

Ensuring Quality of Regulatory Clinical Documents

RUTGERS IJOBS WORKSHOP REGULATORY WRITING JANUARY 30, 2018

Academia to Industry and Back

Emerging Trends in Regulatory Outsourcing WHITE PAPER.

Regulatory progress for innovation/international trend on pharmaceutical regulatory convergence Introduction of Horizon Scanning in ICMRA

The Role of the Writer in Regulatory Affairs. Julie Bowdler 19 May 2014

Novartis Business Services HR University Relations. Clinical Sciences and Innovation. Postgraduate Program

CONTRACT RESEARCH SERVICES

May 9, Creating a Successful Global Value Dossier

Drug Development Services

OVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS IN EMERGING MARKET

Simplifying Clinical Trials

Clinical Data Management Services

Cardinal Health Specialty Solutions. Bringing a new drug to life. Regulatory Sciences

Introduction to CMC Regulatory Affairs

CAREER DEVELOPMENT FOR EXPERIENCED REGULATORY PROFESSIONALS

Regulatory requirements and registration process of Generic Drugs in China

EARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS

University of Pennsylvania Biomedical and Life Sciences Career Fair

A SHORT GUIDE TO THE PROCEDURE FOR A CLINICAL TRIAL APPLICATION IN THE KINGDOM OF BAHRAIN

Envigo Corporate & Industry Overview. Rutgers University

Regulatory Updates in Taiwan

HUMAN CHALLENGE TESTING

Impact of MRCT after ICH E17 fully implement -Industry perspective-

DIFFERING CMC REQUIREMENTS: US AND EU

Planning of Application

BIOMETRICS SERVICES ADVISORY DATA OFFICE UNBLINDING SECURE INDEPENDENT TEAM PROGRAM. ADaM TRAINER SAFETY SDTM COMPLIANT TA-EXPERTISE SDTM DATA

Your Complete Quality Solution Provider for the Life Science Industry

Global Development of Drugs and Co-operation among Asian Economies

An Introduction to Clinical Research and Development

THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH

Capillary Electrophoresis in Global Emerging Markets: A Regulatory Perspective. Brian K. Nunnally, Ph.D.

(Historic Developments Undertaken by CFDA)

University joins Industry: Clinical Trials & Drug Safety. Aula Magna-Facultad de Farmacia 11 Marzo 2015

Our story. Today we serve our clients with pride, agility & compliance with the professionalism that they seek for.

We set things in motion and keep them moving. Metronomia Clinical Research Services

Medical Information Role in the Pharmaceutical Industry

Clinical Trials A Closer Look

The Investigator s Brochure: A multidisciplinary document

Overview of global registration of vaccines

Considerations for Global Development of Orphan Drugs. Ginny Beakes-Read Executive Director Global Regulatory Policy and Intelligence Eisai, Inc.

ROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016

OCTC 2012 CRO Selection

Trends in pharmacovigilance inspection deviations. 8th Scandinavian SARQA/DKG Quality Assurance Conference

Impact factor: 3.958/ICV: 4.10 ISSN:

Career in Biotechnology Industry. Novartis Biocamp Roadshow

ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective

The Hiring Process in Academia. Will focus primarily on tenure-track process

New Regulation in Japan and Future Direction of PMDA. Tatsuya Kondo, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA)

Regulations of Biologics in Taiwan

Pre-consultation system at the authority for clinical trials and NDA in Japan

GLOBAL Trend and opportunities in drug development

Investigational New Drug Application

Syllabus for M.Pharm Clinical Research Semester II

Analyze Samples: Job Posting and Resumes Overview

Document Reuse: Theory and Practice

US FDA and International Regulatory Efforts in Cellular and Gene Therapies

PhUSE Single Day Event 2009, Frankfurt

The Practical Application of Regulatory Science

Optimize Your Medical Affairs Team s Influence in a Start-up Organization

Data Quality and Integrity: From Clinical Monitoring to Marketing Approval

Welcome. Thank you for joining us. Irina Moissiu, Director Client Relations Laurie Furiness, EVP Operations & Consulting Services

Your bridge to. better medicines

NUVISAN GROUP. Our Philosophy

Continuous Manufacturing PMDA s Perspective

The 6 th Kitasato-Harvard Symposium Session3:New Challenges Disease Areas. Investigator Initiated Trial (IIT) Future for IIT from the past experience

Finding the right partner for preclinical into phase I. Facts, Threats & Opportunities

Sponsoring an IND? Ignorance is Not Always Blissful

A drug development crossroad lies ahead

NON-FDA INVESTIGATOR-INITIATED PROTOCOL TEMPLATE

Policy Appendix IV: DRCR.net Industry Collaboration Policies Version 5.0, February 2, 2009

Tier Assessment/Setting - Quick Guide to Competency Levels

Policy Appendix IV: DRCR.net Industry Collaboration Policies Version 6.0, August 2, 2017

DIA Document & Records Management SIAC

Putting CDISC Standards to Work How Converting to CDISC Standards Early in the Clinical Trial Process Will Make Your CDISC Investment Pay

Grindeks years of growth

Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales

Advanced Therapies in Europe

PharmaSUG Paper IB15

Executive Search. Chief Standards Officer

Evolving Regulatory Guidance on Submission of Standardized Data. James R. Johnson, PhD RTP CDISC User Network

CHALLENGES OF GLOBAL CLINICAL TRIAL SUPPLY SOURCING SOME SPECIFICS FOR EMERGING MARKETS

Some challenges in the development of new toxicity assays using in vitro methods

Quality Assurance in Clinical Trials

The role of the Clinical Trials Unit Emma Hall PhD CStat Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU)

Int. J. Pharm. Sci. Rev. Res., 31(2), March April 2015; Article No. 04, Pages: A Review on Drug Approval in Regulated and Non-Regulated Markets

Job Title: Head, Clinical Science Job Location: Nanjing, China CV to: Wechat:

elearning Catalog DIAglobal.org/eLearning

Corporate Presentation. October 2017

KINGSMANN CARE GROUP

Sandoz Talent Excellence Program. Shaping the future of healthcare. Program Overview. Published on Sandoz US (

Ensuring patient safety and regulatory compliance in an era of ever expanding complexity: Key considerations for today s pharmacovigilance leader

Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario

Global Clinical Trials in Korea

Transcription:

MSCI 689: Career Development for the Biomedical PhD Scientist Introduction to Medical Writing and Drug Development Danielle K Lewis, PhD April 28, 2017

One-Stop Shop Regulatory Submissions Regulatory Operations Regulatory Affairs Medical Writing & Disclosure Services Clinical Programming Biostatistics Data Management Medical Information Drug Safety & PV Clinical Development Support Data Abstraction GMP & GLP Services www.mmsholdings.com 2

Objectives Definition/Description of Medical Writing Drug Approval Process Discuss How the Documents We Write Fit into This Process Transitioning from Academia to Med Writing Tips and Tricks to Get That First Look 3

Medical Writing The art of communicating clinical and scientific data and information different from manuscript writing Communicates the effects of treatments/medications (interventions) on human subjects during clinical studies. Describes non-interventional (epidemiology, methodology, longitudinal etc.) study events and results in clinical study reports (CSRs). It also communicates the risk of a drug as well as the company plan for monitoring and negating those risks. 4

It is Global 5

Medical writing We submit documents all over the globe (eg, US, EU, Japan, Russia, Jordan, Brazil, Colombia, Mexico, South Africa, Thailand, Taiwan, Vietnam, ) 6

Medical Writing An ideal medical document/presentation is prepared with the audience in mind. The audience might be: A clinical/scientific team A government agency (FDA, EMA, PMDA) An objective 3 rd party reviewer/expert in the field A product consumer/public A well-written document will accurately present the information and successfully communicate the outcome in the most concise manner possible. 7

Medical Writing Questions medical writers ask about the documents they are writing: What is its purpose? Who is the target audience? What type of publication is it? Does a template exist? Are there previous similar documents that can be used as a guide? What are the proposed start and finish dates? Is there a specific style guideline/format that should be followed? Who will sign off on the document and at what stages? 8

Types of Documents Written by MMS Regulatory /Clinical Investigational new drug (IND) Clinical study protocol Case report form (CRF) Clinical study report (CSR) Common technical document (CTD) New drug application (NDA) Marketing authorization application (MAA) Summary of clinical efficacy (SCE) Summary of clinical safety (SCS) Orphan drug application Investigator s brochure (IB) update Briefing book/package Regulatory response Global feasibility document Risk management plan (RMP) Lay Summaries Marketing Academy of Managed Care Pharmacy (AMCP) dossier Medical slide deck Educational Medical training document Competitive intelligence Abstract Manuscript Poster 9

Drug Approval Process: Timeline, Documents Pre- Clinical Phase 1 Phase 2 Phase 3 Phase 4 Pre-IND Mtg IND Filing End of Ph2 Mtg Pre-licensing Mtg Approval NDA Filing Briefing Document IND IB CSRs Study documents: protocol; SAP; CRFs; table requirements) Briefing Document Briefing Document CTD Query Response PSURs (updated every 6 months) Annual Updates to IND, IB 10

Drug Approval Process: Clinical Trials Types of Clinical Trials in Humans Phase I: Try to determine dosing, document how a drug is metabolized and excreted, and identify acute side effects. Subjects: usually between 20 and 80 healthy volunteers Phase 2: Gather further safety data and preliminary evidence of the drug's beneficial effects (efficacy), and develop and refine research methods for future trials with this drug. Subjects: approximately 100-300 people who have the disease or condition that the product potentially could treat. Phase 3: Further test the product's effectiveness, monitor side effects, and, in some cases, compare the product's effects to a standard treatment, if one is already available. Subjects: approximately 1,000-3,000 people with the disease. These studies also help define the safety profile of the drug 11

Drug Approval Process: Timeline, Documents Pre- Clinical Phase 1 Phase 2 Phase 3 Phase 4 Pre-IND Mtg IND Filing End of Ph2 Mtg Pre-licensing Mtg Approval NDA Filing Briefing Document IND IB CSRs Study documents: protocol; SAP; CRFs; table requirements and RMPs (for EMA) Briefing Document Briefing Document CTD Query Response PSURs (updated every 6 months) Annual Updates to IND, IB 12

Application for marketing authorization 13

Drug Approval Process: Timeline, Documents Pre- Clinical Phase 1 Phase 2 Phase 3 Phase 4 Pre-IND Mtg IND Filing End of Ph2 Mtg Pre-licensing Mtg Approval NDA Filing Briefing Document IND IB CSRs Study documents: protocol; SAP; CRFs; table requirements and RMPs (for EMA) Briefing Document Briefing Document CTD Query Response PSURs (updated every 6 months) Annual Updates to IND, IB 14

OK so what do you DO as a medical writer????? Writing Client interaction Manage timelines Set meetings up with client, go over client/writer expectations Usually work within a document management system of the client Interact with teams of 4 to 15 people and incorporate comments from said team. Emails, phone calls, SOP driven there is a defined process for everything 15

How do you transition from academia? My personal experience PhD Neuroscience Over 15 years of research Laboratory Skill Set Animal care surgery Had multiple projects to manage Wrote SOP and animals use protocols for lab Worked by myself for HOURS Wrote papers Lectured Team driven science 16

Come up with a new brand for yourself Laboratory Skill Set Animal care surgery - Had multiple projects to manage Wrote SOP and animals use protocols for lab Worked by myself for HOURS Had published scientific manuscripts Lectured Team-driven science Medical Writing Skill Set Ability to manage multiple timelines Writing skills Work independently Writing skills Can communicate effectively with people Ability to work in a team environment 17

How do you transition into Medical Writing? Write, write, write Informational interviews..network Publications, SOPs, laboratory safety, animal use protocols, grant writing Online sources: Upwork, The HittList, American Medical Writers Association Internships Showcase your skills Management and organizational skill set Teaching experience translates to ability to communicate effectively Meeting deadlines medical writing is driven by timelines 18

Pros and Cons of Medical Writing Pros Can do your job anywhere with secure wifi The documents are fun and interesting Job outlook is great Sense of accomplishment Cons Can do your job anywhere with secure wifi Teams can be difficult Spend a lot of time sitting 19

MMS Holdings Inc. MMS is a clinical research organization (CRO) based in Canton, MI. Worldwide presence (India, Europe, Japan, China, Middle East, South Africa) MMS is a growing company More than 20 new clients in 2016 34 new medical writers were hired at US and EU sites in 2016 20

MMS Work Environment Professional colleagues On-site training Benefits: PTO, 401K with Employer Match, Life/Health Insurance, Flex Accounts, On-site Yoga and Chair Massages, Company Events 21

Questions? 22

Contact information Danielle K Lewis lewisdani67@gmail.com 23

Thank You! For additional information or questions regarding our services, visit our website: www.mmsholdings.com or Contact MMS: info@mmsholdings.com Scan with your smartphone or tablet to go to our website for more details. 24

Revision History Date Reason(s) Author(s) 06/13/2013 Original Philip Jessmon 02/12/2015 Updated for outreach opportunities 02/22/2017 Updated for Professional Development Series at UT/ new slide deck 04/28/2017 Updated for Texas A & M Career Development for the Biomedical PhD Scientist Lecture Teresa Cesena Jean Overmeyer Danielle Lewis 25